Get started
Author

A. Shvyrkova

Observed names: Anastasia Shvyrkova, Anastasiia Shvyrkova
ORCID: 0000-0002-8742-6295
Observed ORCID: 0000-0002-8742-6295
OpenAlex ID: A5114977076
Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2024 · Glenn J. Hanna, L. B. Oakley, et al. · Clinical Cancer Research · 10
PDF
RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation
2025 · Vladimir Kushnarev, Danil Stupichev, et al. · Scientific Reports · 3
PDF
Evaluation of gene expression assays to classify large B-cell lymphoma by molecular subtype using formalin-fixed paraffin-embedded tumor biopsies
2026 · Neha Akkad, Laura K. Hilton, et al. · Blood Cancer Journal
PDF
Supplemental Appendix 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Data from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 7 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 4 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 6 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 3 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 4 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Appendix 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 7 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 6 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 3 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Works count: 20
Citation count: 13
H-index: 2
I10-index: 1
Year
Topic
Type